Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
The Microbiota Makes for Good Therapy: The gut microbiota has been implicated in the development of some cancers, such as colorectal cancer, but—given the important role our intestinal habitants play in metabolism—they may also modulate the efficacy of certain cancer therapeutics. Iida et al. (p. 967 ) evaluated the impact of the microbiota on the efficacy of an immunotherapy [CpG (the cytosine, guanosine, phosphodiester link) oligonucleotides] and oxaliplatin, a platinum compound used as a chemotherapeutic. Both therapies were reduced in efficacy in tumor-bearing mice that lacked microbiota, with the microbiota important for activating the innate immune response against the tumors. Viaud et al. (p. 971 ) found a similar effect of the microbiota on tumor-bearing mice treated with cyclophosphamide, but in this case it appeared that the microbiota promoted an adaptive immune response against the tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In mouse models, certain gut commensals mediate efficacy of anticancer therapies, including chemotherapy, radiotherapy, and immunotherapies such as adoptive T cell transfer, intratumoral CpG-oligonucleotides, and ICIs.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, broad-spectrum antibiotics (mainly beta-lactams) taken prior to immunotherapy markedly reduce the clinical benefit of ICIs, chimeric antigen receptor (CAR)-T cells, stem cell transplantation in patients, and immunogenic chemotherapy in preclinical tumor models.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The gut microbiome has been shown to have multiple effects on tumor biology, such as the transformation process, tumor progression, and the response to anticancer therapies including immunotherapy (21-29).”
From The human tumor microbiome is composed of tumor type–specific intracellular bacteria (2020) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Given these considerations, it is perhaps even more striking that bacteria generally associated with health (such as Clostridiales, Ruminococcacae, Faecalibacterium spp., Akkermansia muciniphila, B. fragilis,a n dBifidobacteria) (13, 14, 18-20) or immunogenicity (Enterococci, Collinsella, and Alistipes)( 11, 13, 14, 20) were found to be abundant in responding patients.”
From The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies (2018) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The explanation is that commensal microbiome members within the gut of the mice might produce TLR agonists, thus promoting the rise of an oxidative stress milieu and tumor cell death.”
From Gut Microbiota and Cancer: From Pathogenesis to Therapy (2019) · cites this paper as [165]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
Irizarry, R. A. (2003) · Biostatistics · doi:10.1093/biostatistics/4.2.249 · Cited by 10,603
An automated method for finding molecular complexes in large protein interaction networks
Bader, G. D., & Hogue, C. W. (2003) · BMC Bioinformatics · doi:10.1186/1471-2105-4-2 · Cited by 6,072
Cytoscape 2.8: new features for data integration and network visualization
Smoot, M. E., Ono, K., Ruscheinski, J., Wang, P.-L., & Ideker, T. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btq675 · Cited by 4,830
The impact of the gut microbiota on human health: an integrative view
Clemente, J. C., Ursell, L. K., Parfrey, L. W., & Knight, R. (2012) · Cell · doi:10.1016/j.cell.2012.01.035 · Cited by 3,710
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Direct multiplexed measurement of gene expression with color-coded probe pairs
Geiss, G. K., Bumgarner, R. E., Birditt, B., Dahl, T., Dowidar, N., Dunaway, D. L., Fell, H. P., Ferree, S., George, R. D., Grogan, T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1385 · Cited by 2,066
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Cited by
Items 101–200 of 258
Metabolic reprogramming for cancer cells and their microenvironment: Beyond the Warburg Effect
Sun, L., Suo, C., Li, S.-T., Zhang, H., & Gao, P. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.06.005 · Cited by 363
Gut microbiome in HCC – Mechanisms, diagnosis and therapy
Schwabe, R. F., & Greten, T. F. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.016 · Cited by 363
Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications
Zhao, L.-Y., Mei, J.-X., Yu, G., Lei, L., Zhang, W.-H., Liu, K., Chen, X.-L., Kołat, D., Yang, K., & Hu, J.-K. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01406-7 · Cited by 359
“For example, OMVs released by H. pylori harbor active CagA that activates TLR and NF-κB pathways in gastric cells, which reinforces the inflammation and cell proliferation associated with carcinogenesis.107,108 In addition, certain microbial metabolites may be involved in the formation of the TME.”
BackgroundInfluentialMetal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
Environmental Factors, Gut Microbiota, and Colorectal Cancer Prevention
Song, M., & Chan, A. T. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.07.012 · Cited by 355
The Intestinal Metabolome: An Intersection Between Microbiota and Host
Ursell, L. K., Haiser, H. J., Van Treuren, W., Garg, N., Reddivari, L., Vanamala, J., Dorrestein, P. C., Turnbaugh, P. J., & Knight, R. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.03.001 · Cited by 355
Mitochondrial oxidative stress in the tumor microenvironment and cancer immunoescape: foe or friend?
Kuo, C.-L., Ponneri Babuharisankar, A., Lin, Y.-C., Lien, H.-W., Lo, Y. K., Chou, H.-Y., Tangeda, V., Cheng, L.-C., Cheng, A. N., & Lee, A. Y.-L. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00859-2 · Cited by 351
Microbiome and colorectal cancer: Roles in carcinogenesis and clinical potential
Saus, E., Iraola-Guzmán, S., Willis, J. R., Brunet-Vega, A., & Gabaldón, T. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.05.001 · Cited by 350
Understanding and targeting resistance mechanisms in cancer
Lei, Z., Tian, Q., Teng, Q., Wurpel, J. N. D., Zeng, L., Pan, Y., & Chen, Z. (2023) · MedComm · doi:10.1002/mco2.265 · Cited by 347
Probiotic Bacteria: A Promising Tool in Cancer Prevention and Therapy
Górska, A., Przystupski, D., Niemczura, M. J., & Kulbacka, J. (2019) · Current Microbiology · doi:10.1007/s00284-019-01679-8 · Cited by 344
Bacteria in cancer initiation, promotion and progression
El Tekle, G., & Garrett, W. S. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00594-2 · Cited by 343
Dupaul-Chicoine, J., Arabzadeh, A., Dagenais, M., Douglas, T., Champagne, C., Morizot, A., Rodrigue-Gervais, I. G., Breton, V., Colpitts, S. L., Beauchemin, N., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.08.013 · Cited by 342
“The commensal microbiota was required for promoting cytotoxicity after chemotherapy by modulating the tumor microenvironment (Iida et al., 2013; Viaud et al., 2013).”
BackgroundThe Oral Microbiome and Cancer
Irfan, M., Delgado, R. Z. R., & Frias-Lopez, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.591088 · Cited by 341
“These discoveries underscore the significance of the microbiome in the outcomes of sickness treatment (174).”
BackgroundInfluentialAdvancing functional and translational microbiome research using meta-omics approaches
Zhang, X., Li, L., Butcher, J., Stintzi, A., & Figeys, D. (2019) · Microbiome · doi:10.1186/s40168-019-0767-6 · Cited by 340
Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation
Peled, J. U., Devlin, S. M., Staffas, A., Lumish, M., Khanin, R., Littmann, E. R., Ling, L., Kosuri, S., Maloy, M., Slingerland, J. B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.3348 · Cited by 325
Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis
Pernigoni, N., Zagato, E., Calcinotto, A., Troiani, M., Mestre, R. P., Calì, B., Attanasio, G., Troisi, J., Minini, M., Mosole, S., et al. (2021) · Science · doi:10.1126/science.abf8403 · Cited by 323
The Role of the Gut Microbiome in Colorectal Cancer Development and Therapy Response
Sánchez-Alcoholado, L., Ramos-Molina, B., Otero, A., Laborda-Illanes, A., Ordóñez, R., Medina, J. A., Gómez-Millán, J., & Queipo-Ortuño, M. I. (2020) · Cancers · doi:10.3390/cancers12061406 · Cited by 337
Emerging roles of ECM remodeling processes in cancer
Mohan, V., Das, A., & Sagi, I. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.004 · Cited by 334
Individualized Medicine from Prewomb to Tomb
Topol, E. J. (2014) · Cell · doi:10.1016/j.cell.2014.02.012 · Cited by 333
Pericellular Hydrogel/Nanonets Inhibit Cancer Cells
Kuang, Y., Shi, J., Li, J., Yuan, D., Alberti, K. A., Xu, Q., & Xu, B. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201402216 · Cited by 333
The gut microbial metabolite formate exacerbates colorectal cancer progression
Ternes, D., Tsenkova, M., Pozdeev, V. I., Meyers, M., Koncina, E., Atatri, S., Schmitz, M., Karta, J., Schmoetten, M., Heinken, A., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00558-0 · Cited by 333
Factors involved in cancer metastasis: a better understanding to “seed and soil” hypothesis
Liu, Q., Zhang, H., Jiang, X., Qian, C., Liu, Z., & Luo, D. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0742-4 · Cited by 332
Mocanu, V., Zhang, Z., Deehan, E. C., Kao, D. H., Hotte, N., Karmali, S., Birch, D. W., Samarasinghe, K. K., Walter, J., & Madsen, K. L. (2021) · Nature Medicine · doi:10.1038/s41591-021-01399-2 · Cited by 328
Nanomedicine for tumor microenvironment modulation and cancer treatment enhancement
Liu, J., Chen, Q., Feng, L., & Liu, Z. (2018) · Nano Today · doi:10.1016/j.nantod.2018.06.008 · Cited by 327
Lee, S.-H., Cho, S.-Y., Yoon, Y., Park, C., Sohn, J., Jeong, J.-J., Jeon, B.-N., Jang, M., An, C., Lee, S., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-020-00831-6 · Cited by 325
Gut microbiome, big data and machine learning to promote precision medicine for cancer
Cammarota, G., Ianiro, G., Ahern, A., Carbone, C., Temko, A., Claesson, M. J., Gasbarrini, A., & Tortora, G. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0327-3 · Cited by 324
Liu, X., Shao, L., Liu, X., Ji, F., Mei, Y., Cheng, Y., Liu, F., Yan, C., Li, L., & Ling, Z. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.034 · Cited by 322
Overacre-Delgoffe, A. E., Bumgarner, H. J., Cillo, A. R., Burr, A. H. P., Tometich, J. T., Bhattacharjee, A., Bruno, T. C., Vignali, D. A. A., & Hand, T. W. (2021) · Immunity · doi:10.1016/j.immuni.2021.11.003 · Cited by 318
Exploring the emerging role of the microbiome in cancer immunotherapy
Fessler, J., Matson, V., & Gajewski, T. F. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0574-4 · Cited by 319
Zhang, S., Yang, Y., Weng, W., Guo, B., Cai, G., Ma, Y., & Cai, S. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0985-y · Cited by 316
Rutkowski, M. R., Stephen, T. L., Svoronos, N., Allegrezza, M. J., Tesone, A. J., Perales-Puchalt, A., Brencicova, E., Escovar-Fadul, X., Nguyen, J. M., Cadungog, M. G., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.009 · Cited by 311
“…mice, there is an increased systemic TLR5 signaling is driving differential tumor-promoting inflamm outcome of malignant progression. been demonstrated to have a crucial role in therapeutic responses for tumors occurring outside of the intestinal tract (Iida et al., 2013; Viaud et al., 2013).”
Microbiota, Inflammation and Colorectal Cancer
Lucas, C., Barnich, N., & Nguyen, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061310 · Cited by 313
Sambi, M., Bagheri, L., & Szewczuk, M. R. (2019) · Journal of Oncology · doi:10.1155/2019/4508794 · Cited by 313
Unexpected guests in the tumor microenvironment: microbiome in cancer
Wong-Rolle, A., Wei, H. K., Zhao, C., & Jin, C. (2021) · Protein & Cell · doi:10.1007/s13238-020-00813-8 · Cited by 313
Tissue-specific tumorigenesis: context matters
Schneider, G., Schmidt-Supprian, M., Rad, R., & Saur, D. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.5 · Cited by 311
Gut microbiota injury in allogeneic haematopoietic stem cell transplantation
Shono, Y., & van den Brink, M. R. M. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.10 · Cited by 309
Uncovering effects of antibiotics on the host and microbiota using transkingdom gene networks
Morgun, A., Dzutsev, A., Dong, X., Greer, R. L., Sexton, D. J., Ravel, J., Schuster, M., Hsiao, W., Matzinger, P., & Shulzhenko, N. (2015) · Gut · doi:10.1136/gutjnl-2014-308820 · Cited by 306
Self-citationTrial Watch: Immunogenic cell death inducers for anticancer chemotherapy
Pol, J., Vacchelli, E., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., Sautès-Fridman, C., Fucikova, J., Galon, J., Spisek, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008866 · Cited by 305
The Human Microbiome and Cancer
Rajagopala, S. V., Vashee, S., Oldfield, L. M., Suzuki, Y., Venter, J. C., Telenti, A., & Nelson, K. E. (2017) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-16-0249 · Cited by 303
Li, B., Li, L., Li, M., Lam, S. M., Wang, G., Wu, Y., Zhang, H., Niu, C., Zhang, X., Liu, X., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.015 · Cited by 302
The Role of the Microbiota in Inflammation, Carcinogenesis, and Cancer Therapy
Dzutsev, A., Goldszmid, R. S., Viaud, S., Zitvogel, L., & Trinchieri, G. (2015) · European Journal of Immunology · doi:10.1002/eji.201444972 · Cited by 300
Self-citationDzutsev, A., Badger, J. H., Perez-Chanona, E., Roy, S., Salcedo, R., Smith, C. K., & Trinchieri, G. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052133 · Cited by 302
Self-citationColorectal liver metastasis: molecular mechanism and interventional therapy
Zhou, H., Liu, Z., Wang, Y., Wen, X., Amador, E. H., Yuan, L., Ran, X., Xiong, L., Ran, Y., Chen, W., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00922-2 · Cited by 298
Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies
Panebianco, C., Andriulli, A., & Pazienza, V. (2018) · Microbiome · doi:10.1186/s40168-018-0483-7 · Cited by 298
ROS-modulated therapeutic approaches in cancer treatment
Raza, M. H., Siraj, S., Arshad, A., Waheed, U., Aldakheel, F., Alduraywish, S., & Arshad, M. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2464-9 · Cited by 297
Role of the Gut Microbiota and Its Metabolites in Tumorigenesis or Development of Colorectal Cancer
Qu, R., Zhang, Y., Ma, Y., Zhou, X., Sun, L., Jiang, C., Zhang, Z., & Fu, W. (2023) · Advanced Science · doi:10.1002/advs.202205563 · Cited by 297
Chalabi, M., Cardona, A., Nagarkar, D. R., Dhawahir Scala, A., Gandara, D. R., Rittmeyer, A., Albert, M. L., Powles, T., Kok, M., & Herrera, F. G. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.006 · Cited by 294
Targeting the gut microbiota for cancer therapy
Fernandes, M. R., Aggarwal, P., Costa, R. G. F., Cole, A. M., & Trinchieri, G. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00513-x · Cited by 290
Self-citationMicrobiome, Metagenomics, and High-Dimensional Compositional Data Analysis
Li, H. (2015) · Annual Review of Statistics and Its Application · doi:10.1146/annurev-statistics-010814-020351 · Cited by 288
Gut microbiota is critical for the induction of chemotherapy-induced pain
Shen, S., Lim, G., You, Z., Ding, W., Huang, P., Ran, C., Doheny, J., Caravan, P., Tate, S., Hu, K., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4606 · Cited by 286
Oxidative Stress in the Tumor Microenvironment and Its Relevance to Cancer Immunotherapy
Aboelella, N. S., Brandle, C., Kim, T., Ding, Z.-C., & Zhou, G. (2021) · Cancers · doi:10.3390/cancers13050986 · Cited by 286
Gut Microbiota Modulation of Efficacy and Toxicity of Cancer Chemotherapy and Immunotherapy
Chrysostomou, D., Roberts, L. A., Marchesi, J. R., & Kinross, J. M. (2023) · Gastroenterology · doi:10.1053/j.gastro.2022.10.018 · Cited by 283
Dysbiosis of gut microbiota in promoting the development of colorectal cancer
Zou, S., Fang, L., & Lee, M.-H. (2018) · Gastroenterology Report · doi:10.1093/gastro/gox031 · Cited by 280
Akkermansia muciniphila mediates negative effects of IFNγ on glucose metabolism
Greer, R. L., Dong, X., Moraes, A. C. F., Zielke, R. A., Fernandes, G. R., Peremyslova, E., Vasquez-Perez, S., Schoenborn, A. A., Gomes, E. P., Pereira, A. C., et al. (2016) · Nature Communications · doi:10.1038/ncomms13329 · Cited by 279
The influence of gut microbiota on drug metabolism and toxicity
Li, H., He, J., & Jia, W. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1121234 · Cited by 278
Gajewski, T. F., Corrales, L., Williams, J., Horton, B., Sivan, A., & Spranger, S. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-67577-0_2 · Cited by 278
Bacteria-triggered tumor-specific thrombosis to enable potent photothermal immunotherapy of cancer
Yi, X., Zhou, H., Chao, Y., Xiong, S., Zhong, J., Chai, Z., Yang, K., & Liu, Z. (2020) · Science Advances · doi:10.1126/sciadv.aba3546 · Cited by 276
Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy
Shiao, S. L., Kershaw, K. M., Limon, J. J., You, S., Yoon, J., Ko, E. Y., Guarnerio, J., Potdar, A. A., McGovern, D. P. B., Bose, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.002 · Cited by 275
Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes
Ting, N. L.-N., Lau, H. C.-H., & Yu, J. (2022) · Gut · doi:10.1136/gutjnl-2021-326264 · Cited by 274
Desired Turbulence? Gut-Lung Axis, Immunity, and Lung Cancer
Bingula, R., Filaire, M., Radosevic-Robin, N., Bey, M., Berthon, J.-Y., Bernalier-Donadille, A., Vasson, M.-P., & Filaire, E. (2017) · Journal of Oncology · doi:10.1155/2017/5035371 · Cited by 270
Adjusting microbiome profiles for differences in microbial load by spike-in bacteria
Stämmler, F., Gläsner, J., Hiergeist, A., Holler, E., Weber, D., Oefner, P. J., Gessner, A., & Spang, R. (2016) · Microbiome · doi:10.1186/s40168-016-0175-0 · Cited by 269
The microbiota and microbiome in pancreatic cancer: more influential than expected
Wei, M.-Y., Shi, S., Liang, C., Meng, Q.-C., Hua, J., Zhang, Y.-Y., Liu, J., Zhang, B., Xu, J., & Yu, X.-J. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1008-0 · Cited by 268
Drug-microbiota interactions: an emerging priority for precision medicine
Zhao, Q., Chen, Y., Huang, W., Zhou, H., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01619-w · Cited by 268
Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics
Carmody, R. N., & Turnbaugh, P. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72335 · Cited by 268
“Confirming this pattern, Tnf expression was positively correlated with the abundance of the Gram-negative genus Alistipes , and inoculation by Alistipes after antibiotic treatment rescued TNF production (82).”
Host-microbe co-metabolism dictates cancer drug efficacy in C. elegans
Scott, T. A., Quintaneiro, L. M., Norvaisas, P., Lui, P. P., Wilson, M. P., Leung, K.-Y., Herrera-Dominguez, L., Sudiwala, S., Pessia, A., Clayton, P. T., et al. (2017) · Cell · doi:10.1016/j.cell.2017.03.040 · Cited by 254
“454 Cell 169, 442–456, April 20, 2017 Role of Diet and Drugs in Fluoropyrimidine Efficacy Interventions that disrupt the microbiota, such as antibiotics, impair the response of tumors to CpG-oligonucleotide immunotherapy and platinum chemotherapy (Iida et al., 2013).”
BackgroundTrial watch: Chemotherapy with immunogenic cell death inducers
Vacchelli, E., Senovilla, L., Eggermont, A., Fridman, W. H., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.23510 · Cited by 265
Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model.
Gui, Q.-F., Lu, H.-F., Zhang, C.-X., Xu, Z.-R., & Yang, Y.-H. (2015) · Genetics and Molecular Research · doi:10.4238/2015.may.25.16 · Cited by 262
Microbiota-Induced Type I Interferons Instruct a Poised Basal State of Dendritic Cells
Schaupp, L., Muth, S., Rogell, L., Kofoed-Branzk, M., Melchior, F., Lienenklaus, S., Ganal-Vonarburg, S. C., Klein, M., Guendel, F., Hain, T., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.022 · Cited by 263
Hou, H., Chen, D., Zhang, K., Zhang, W., Liu, T., Wang, S., Dai, X., Wang, B., Zhong, W., & Cao, H. (2022) · Cancer Letters · doi:10.1016/j.canlet.2021.11.027 · Cited by 263
Potential Role of the Gut Microbiome In Colorectal Cancer Progression
Kim, J., & Lee, H. K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.807648 · Cited by 259
Beckmann, J. S., & Lew, D. (2016) · Genome Medicine · doi:10.1186/s13073-016-0388-7 · Cited by 258
Gut microbiome and cancer immunotherapy
Li, W., Deng, Y., Chu, Q., & Zhang, P. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.01.015 · Cited by 253
Microbiota-mediated inflammation and antimicrobial defense in the intestine
Caballero, S., & Pamer, E. G. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120238 · Cited by 238
Elkrief, A., Derosa, L., Kroemer, G., Zitvogel, L., & Routy, B. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz206 · Cited by 246
Martínez-López, M., Iborra, S., Conde-Garrosa, R., Mastrangelo, A., Danne, C., Mann, E. R., Reid, D. M., Gaboriau-Routhiau, V., Chaparro, M., Lorenzo, M. P., et al. (2019) · Immunity · doi:10.1016/j.immuni.2018.12.020 · Cited by 228
Zhu, X., Li, K., Liu, G., Wu, R., Zhang, Y., Wang, S., Xu, M., Lu, L., & Li, P. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2249143 · Cited by 220
Elkrief, A., El Raichani, L., Richard, C., Messaoudene, M., Belkaid, W., Malo, J., Belanger, K., Miller, W., Jamal, R., Letarte, N., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1568812 · Cited by 208
“a causality between ATB and primary resistance to ICI and immunogenic chemotherapy.(8,12,24,25) Lastly, in our study, the frequency of immune-related adverse effects was too small and we were unable to evaluate the association between ATB and adverse events.”
BackgroundThe promise of the gut microbiome as part of individualized treatment strategies
Schupack, D. A., Mars, R. A. T., Voelker, D. H., Abeykoon, J. P., & Kashyap, P. C. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00499-1 · Cited by 217
Elinav, E., Garrett, W. S., Trinchieri, G., & Wargo, J. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0155-3 · Cited by 215
Self-citationMicrobiota effects on cancer: From risks to therapies
Rea, D., Coppola, G., Palma, G., Barbieri, A., Luciano, A., Del Prete, P., Rossetti, S., Berretta, M., Facchini, G., Perdonà, S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24681 · Cited by 208
“In addiction oxaliplatin and cisplatin and CpG oligonucleotides (ODN) have also been studied to have an anti-tumor response based on gutmicrobiota interaction: in mice developing subcutaneous lymphomas treated with antibiotics, intestinal bacteria may prime myeloid cells to release reactive-oxygen species (ROS) which…”
BackgroundMyeloid suppressor cells in cancer and autoimmunity
Sica, A., & Massarotti, M. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.07.010 · Cited by 201
Haiser, H. J., Seim, K. L., Balskus, E. P., & Turnbaugh, P. J. (2014) · Gut Microbes · doi:10.4161/gmic.27915 · Cited by 197
Prebiotic-Induced Anti-tumor Immunity Attenuates Tumor Growth
Li, Y., Elmén, L., Segota, I., Xian, Y., Tinoco, R., Feng, Y., Fujita, Y., Segura Muñoz, R. R., Schmaltz, R., Bradley, L. M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.035 · Cited by 189
“Several lines of evidence support the ability of microbiota to enhance the effectiveness of chemotherapy, radiotherapy, and immunotherapy (Alexander et al., 2017; Iida et al., 2013; Roy and Trinchieri, 2017).”
Understanding the role of the gut microbiome in gastrointestinal cancer: A review
Ağagündüz, D., Cocozza, E., Cemali, Ö., Bayazıt, A. D., Nanì, M. F., Cerqua, I., Morgillo, F., Saygılı, S. K., Berni Canani, R., Amero, P., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1130562 · Cited by 189
Clarke, T. B. (2014) · Infection and Immunity · doi:10.1128/iai.02212-14 · Cited by 189
“It is now becoming apparent that this localized view is incorrect and that commensal microbes in the intestine exert a systemic influence on effector cells of the innate immune system at extraintestinal sites, and that this contributes to the establishment of the innate immune set-point (8, 16, 22, 33, 34).”
BackgroundGut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer
Di Modica, M., Gargari, G., Regondi, V., Bonizzi, A., Arioli, S., Belmonte, B., De Cecco, L., Fasano, E., Bianchi, F., Bertolotti, A., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1659 · Cited by 184
Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12
Uribe-Herranz, M., Bittinger, K., Rafail, S., Guedan, S., Pierini, S., Tanes, C., Ganetsky, A., Morgan, M. A., Gill, S., Tanyi, J. L., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.94952 · Cited by 175
“reported that the gut microbiota played a role in activating the innate immune response against cancer (29).”
BackgroundImmunological Mechanisms Underneath the Efficacy of Cancer Therapy
Galluzzi, L., Zitvogel, L., & Kroemer, G. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0197 · Cited by 175
“Amongst other conventional chemotherapeutics, the following molecules directly stimulate the effector activity of myeloid of lymphoid cells: cyclophosphamide (an alkylating agent approved for the treatment of hematologic and solid neoplasms), which favored TH17 and TH1 memory responses, NK-cell and CD8 þ DC expansion…”
BackgroundHelicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies
Oster, P., Vaillant, L., Riva, E., McMillan, B., Begka, C., Truntzer, C., Richard, C., Leblond, M. M., Messaoudene, M., Machremi, E., et al. (2022) · Gut · doi:10.1136/gutjnl-2020-323392 · Cited by 176
“30”
Predictable modulation of cancer treatment outcomes by the gut microbiota
(2020) · doi:10.1186/s40168-020-00811-2 · Cited by 175
Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment
Terrisse, S., Derosa, L., Iebba, V., Ghiringhelli, F., Vaz-Luis, I., Kroemer, G., Fidelle, M., Christodoulidis, S., Segata, N., Thomas, A. M., et al. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-021-00784-1 · Cited by 172
“Mice were treated with CTX or PBS, then randomly assigned to +/− cohousing with humanized mice with HV or BC.”
BackgroundInfluentialMicrobiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?
Derosa, L., Routy, B., Desilets, A., Daillère, R., Terrisse, S., Kroemer, G., & Zitvogel, L. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0236 · Cited by 170
Zhao, S., Gao, G., Li, W., Li, X., Zhao, C., Jiang, T., Jia, Y., He, Y., Li, A., Su, C., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.01.017 · Cited by 164
The microbiome and the hallmarks of cancer
Fulbright, L. E., Ellermann, M., & Arthur, J. C. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006480 · Cited by 164
Halsey, T. M., Thomas, A. S., Hayase, T., Ma, W., Abu-Sbeih, H., Sun, B., Parra, E. R., Jiang, Z.-D., DuPont, H. L., Sanchez, C., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abq4006 · Cited by 161
Microbiome and Breast Cancer: New Role for an Ancient Population
Eslami-S, Z., Majidzadeh-A, K., Halvaei, S., Babapirali, F., & Esmaeili, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00120 · Cited by 153
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
Simpson, R. C., Shanahan, E. R., Scolyer, R. A., & Long, G. V. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00803-9 · Cited by 153
Hayase, E., & Jenq, R. R. (2021) · Genome Medicine · doi:10.1186/s13073-021-00923-w · Cited by 145
Carcinogenesis and therapeutics: the microbiota perspective
Tsilimigras, M. C. B., Fodor, A., & Jobin, C. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2017.8 · Cited by 144
Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy
Thomas, A. M., Fidelle, M., Routy, B., Kroemer, G., Wargo, J. A., Segata, N., & Zitvogel, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00785-8 · Cited by 141
Metadata
- Authors
- Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T., Cramer, S., Dai, R.-M., Kiu, H., Cardone, M., Naik, S., Patri, A. K., Wang, E., Marincola, F. M., Frank, K. M., Belkaid, Y., Trinchieri, G., & Goldszmid, R. S.
- Affiliations
- National Cancer Institute (US)
- National Institute of Allergy and Infectious Diseases (US)
- National Institutes of Health (US)
- Technical Resources International (United States) (US)
- Leidos Biomedical Research Inc. (United States) (US)
- Corresponding author
- Iida, Noriho
- Dzutsev, Amiran
- Stewart, C. Andrew
- Trinchieri, Giorgio
- Goldszmid, Romina S.
- ORCID
- Venue
- Science
- Published
- 2013-11-22
- Volume
- 342
- Issue
- 6161
- Pages
- 967-970
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC6709532
- OpenAlex
- W2124632458
- Cited by
- 2,251
- References
- 36
- Citations by year
- 2026: 100 · 2025: 184 · 2024: 214 · 2023: 251 · 2022: 295 · 2021: 248 · 2020: 247 · 2019: 173 · 2018: 151 · 2017: 124 · 2016: 96 · 2015: 91 · 2014: 71 · 2013: 4
- FWCI
- 38.89
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (ZIABC010793, ZIABC011153)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- gut microbiota, commensal bacteria, tumor microenvironment, cancer immunotherapy, platinum-based chemotherapy, myeloid-derived cells, inflammation, germ-free mice, antibiotic therapy, reactive oxygen species, cytokine production, tumor necrosis, tumor-infiltrating immune cells
- MeSH terms
- Oxaliplatin, Animals, Anti-Bacterial Agents, Antineoplastic Agents, Bacteria, Gene Expression Regulation, Germ-Free Life, Immunotherapy, Inflammation, Intestines, Melanoma, Experimental, Mice, Inbred C57BL, Neoplasm Transplantation, Neoplasms, Oligodeoxyribonucleotides, Organoplatinum Compounds, Phagocytosis, Symbiosis, Tumor Necrosis Factor-alpha, Down-Regulation, Reactive Oxygen Species, Antigen Presentation, Bacterial Physiological Phenomena, Mice, Tumor Microenvironment, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.